Action Okyo Pharma - OKYO

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

91,00

Prix Achat

1,20

Prix Vente

1,60

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

91,00

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma Announces Chairman and CEO Acquire Shares LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO...

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter LONDON and NEW YORK, Jan. 29, 2025 (GLOBE...

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:...

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma...

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE...

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OK-101 is the first drug candidate to...

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in...

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

OKYO - Frequently Asked Questions (FAQ)

What is the current Okyo Pharma share price?

The current share price of Okyo Pharma is 91,00p

What is the 1 year trading range for Okyo Pharma share price?

Okyo Pharma has traded in the range of 0,00p to 0,00p during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
IHCInspiration Healthcare Group Plc	20,30p (50,37%)	439,72k
SEENSeeen Plc	4,75p (46,15%)	1,2M
SCGLSealand Capital Galaxy Limited	3,50p (29,63%)	11,62M
ARGOArgo Group Limited	5,75p (15,00%)	294,32k
ONCOncimmune Holdings Plc	4,46p (14,36%)	252,89k
DEMGDeltex Medical Group Plc	0,025p (-28,57%)	7,82M
DELTDeltic Energy Plc	3,75p (-25,00%)	1,74M
EUZEuropa Metals Ltd	1,35p (-15,63%)	617,67k
SQZSerica Energy Plc	125,00p (-13,19%)	8,66M
AGYAllergy Therapeutics Plc	6,00p (-12,54%)	305,44k
NTVONativo Resources Plc	0,0015p (0,00%)	1,83B
SYMESupply@me Capital Plc	0,0045p (-6,25%)	512,27M
MSMNMosman Oil And Gas Limited	0,038p (-5,00%)	245,25M
PREMPremier African Minerals Limited	0,019p (-7,32%)	136,07M
BZTBezant Resources Plc	0,0245p (2,08%)	76,48M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Okyo Pharma Limited (OKYO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

OKYO Dernières nouvelles

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Okyo Pharma Limited (OKYO) Cours

Okyo Pharma Limited (OKYO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

OKYO Dernières nouvelles

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE